2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
45
Neoplasms
6
Colorectal Neoplasms
5
Neoplasm Metastasis
4
Adenocarcinoma
3
Resectable Pancreatic Cancer
2
Rectal Neoplasms
2
Pancreatic Cancer Metastatic
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Urachal cancer
1
Stomach Neoplasms
1
Pancreatic Ductal Adenocarcinoma (PDAC)
1
Pancreatic Cancer Non-resectable
1
Pancreatic Adenocarcinoma
1
Neoplasms, Basal Cell
1
Locally Advanced Unresectable or Metastatic Solid Tumors
1
Locally Advanced Pancreatic Adenocarcinoma
1
Localized Pancreatic Adenocarcinoma
1
Gastrointestinal Neoplasms
1
Gastroesophageal Adenocarcinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Islet Cell
1
Carcinoma
1
Borderline Resectable Pancreatic Cancer
1
Interventions
Cisplatin
55
Carboplatin
49
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Cetuximab
18
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
13
Sorafenib
12
Radiation
11
Sunitinib
10
Platinum
10
130-nm albumin-bound paclitaxel
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
folfirinox
×
Clear all
NCT04990037
2023-06-29
CAPAFOUR
Cantargia AB
Phase 1
Completed
25 enrolled